LMAT

Business Context and Reporting Period

Company: LeMaitre Vascular, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: LeMaitre Vascular is a global provider of medical devices and implants for the treatment of peripheral vascular disease. The company operates in a single reportable segment, developing, manufacturing, and marketing vascular devices for vascular surgeons. Its portfolio includes 15 product lines across Endovascular, Vascular, and General Surgery categories. The company utilizes a three-pronged growth strategy: expanding a direct sales force, acquiring complementary products, and enhancing in-house manufacturing.

Key Financial Metrics

Note: The company had no outstanding borrowings under its $10 million revolving line of credit as of December 31, 2009.

Material Changes vs. Prior Period

• Profitability Turnaround: The company returned to profitability in 2009, reporting net income of $1.6 million compared to a net loss of $3.3 million in 2008. This was driven by improved gross margins and reduced operating expenses.
• Revenue Growth: Net sales increased 4% to $50.9 million. Growth was primarily driven by higher average selling prices and an 11% increase in the Vascular product category (including $1.1 million in new XenoSure Biologic Vascular Patch sales). This was partially offset by a 7% decline in the Endovascular category due to decreased TAArget Thoracic Stent Graft sales and negative currency fluctuations.
• Gross Margin Expansion: Gross margin improved to 73.3% from 69.6%, attributed to manufacturing efficiencies, higher selling prices, reduced inventory write-downs, and the transition of AlboGraft sales to a direct-to-hospital model in Europe.
• Expense Management: Sales and marketing expenses decreased 10% to $17.7 million, while Research and Development (R&D) expenses increased 11% to $5.9 million due to clinical trial costs.
• Restructuring Charges: Restructuring charges increased to $1.8 million in 2009 from $1.1 million in 2008, primarily due to a $1.8 million charge for the early termination of the AlboGraft distribution agreement with Edwards Lifesciences.

Guidance, Outlook, and Risks

Management Commentary and Outlook:

• Strategic Focus: Management intends to increase operating expenses in 2010 in sales, marketing, R&D, and clinical/regulatory affairs to support growth.
• Regulatory Milestones: The company is conducting pivotal clinical trials (UNITE Trial) for the UniFit Abdominal Stent Graft and a feasibility study (ENTRUST Trial) for the TAArget Thoracic Stent Graft in the U.S. Approval is required for U.S. commercialization.
• Market Trends: The company anticipates continued growth driven by the increasing incidence of peripheral vascular disease and a shift toward minimally invasive endovascular procedures.

Risks and Contingencies:

• Regulatory Approval: Failure to obtain FDA PMA approval for TAArget and UniFit stent grafts would significantly hamper future growth. The FDA previously issued a Warning Letter regarding clinical trial conduct, though corrective actions were deemed adequate in 2008.
• Competition: Intense competition from larger companies (e.g., Medtronic, W.L. Gore) in the aortic stent graft market has affected adoption rates.
• Foreign Currency: Approximately 42% of sales are denominated in foreign currencies (primarily Euro). Fluctuations in exchange rates negatively impacted 2009 results and remain a risk.
• Supply Chain: Reliance on single-source suppliers for key components and third-party manufacturers for certain products creates supply disruption risks.
• Reimbursement: Inadequate third-party reimbursement levels or changes in healthcare policy could reduce demand for products.

Investor Verification Checklist

• Clinical Trial Progress: Verify enrollment numbers and data outcomes for the UNITE (UniFit) and ENTRUST (TAArget) trials, as U.S. market access depends on these results.
• Regulatory Status: Confirm the status of FDA clearance for the TAArget and UniFit devices and any ongoing correspondence regarding the 2008 Warning Letter.
• Endovascular Sales Trend: Monitor the trajectory of Endovascular product sales, specifically the TAArget stent graft, which declined 7% in 2009 due to customer loss and competition.
• Foreign Exchange Exposure: Assess the impact of Euro/USD fluctuations on future revenue, given that 42% of sales are international.
• Direct Sales Transition: Evaluate the success of converting distributor sales to direct sales in Europe (specifically Italy and France) and the impact on gross margins.
• Intellectual Property: Review the status of patent oppositions (e.g., Boston Scientific) and the validity of the sublicense agreement with C.R. Bard for ePTFE technology.